Dr. Christopher Allen Helpert is a Temple, Texas based male Ophthalmologist who is specialized in Ophthalmology. Active license number of Dr. Christopher Allen Helpert is L9731 for Ophthalmology in Texas. Dr. Christopher Allen Helpert is medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, patients can be prescribed vision services, including glasses and contact lenses.
Complete Profile:
Dr. Christopher Allen Helpert speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Ophthalmology
Gender:
Male
Practice Address:
1901 S 1st St, Temple, Texas, 76504-7451
Phone:
254-743-0728
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1851405021
NPI Enumeration Date:
18 Aug, 2006
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Christopher Allen Helpert are as mentioned below.
License Number
Specialization
State
Status
L9731
Ophthalmology
Texas
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
108 Spring Ct, Georgetown, Texas
Zip:
78628-4302
Phone Number:
--
Fax Number:
--
Patients can reach Dr. Christopher Allen Helpert at 1901 S 1st St, Temple, Texas or can call to book an appointment on 254-743-0728. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.